2Q20 Stock Overview
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
QSAM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.00 |
| 52 Week High | US$7.46 |
| 52 Week Low | US$6.38 |
| Beta | 1.81 |
| 1 Month Change | 8.19% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2Q20 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.9% | 0.4% | 0.6% |
| 1Y | n/a | -23.7% | 5.4% |
Return vs Industry: Insufficient data to determine how 2Q20 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2Q20 performed against the German Market.
Price Volatility
| 2Q20 volatility | |
|---|---|
| 2Q20 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2Q20 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2Q20's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | Doug Baum | www.qsambio.com |
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020.
QSAM Biosciences, Inc. Fundamentals Summary
| 2Q20 fundamental statistics | |
|---|---|
| Market cap | €34.35m |
| Earnings (TTM) | -€4.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.1x
P/E RatioIs 2Q20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2Q20 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.16m |
| Earnings | -US$5.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.1% |
How did 2Q20 perform over the long term?
See historical performance and comparison